Gómez RM, Lázaro GR

Language: Spanish
References: 13
Page: 321-324
PDF size: 390.01 Kb.

Text Extraction

Since the introduction in Europe of first-generation drug-eluting stents (DES) in 2002 (the FDA did approved them until 2004), their use quickly grew in Spain and in 2005 exceeded 50 % of all implanted stents (41,352 DES vs. 39,217 conventional stents, Spanish Cardiac Catheterization and Coronary Intervention Registry). According to this registry, there has been a sustained growth until 2011, when 58,211 DES were implanted vs. 36,490 conventional stents (61.47 %). Up until that year (last record available), a total of 428,748 DES had been implemented in Spain. However, variations of use among hospitals and among the autonomous regions, which provide the funds for health, are huge.

REFERENCES

1. Díaz JF, de La Torre JM, Sabaté M, Goicolea J. Registro español de Hemodinámica y Cardiología Intervencionista. XXI Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2011). Rev Esp Cardiol. 2012;65:1106-16.

2. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in sweden. N Engl J Med. 2007;356(10):1009-19.

3. Virmani R, Guagliumi G, Farb A, Musumeci G, Grie-co N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Circulation. 2004;109(6):701-5.

4. Drug-eluting stents for the treatment of coronary artery disease. NICE technology appraisal guidance 152. Part review of NICE technology appraisal guidance 71. Review date: April 2009. [Artículo en Internet]. 2009. [citado 2013 Mar 01]. Disponible en: http://www.nice.org.uk/nicemedia/pdf/TA152Guidance.pdf

5. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of asirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773-80.

6. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-84.

7. Stefanini GG, Holmes DR. Drug-eluting coronary-artery stents. N Engl J Med. 2013; 368(3):254-65.

8. Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(8):977-87.

9. Kelbaek H, Engstrøm T, Ahtarovski, Lønborg J, Vejls-trup N, Pedersen F, et al. Deferred stent implant-ation in patients with ST-segment elevation myo-cardial infarction: a pilot study. EuroIntervention. 2013;8(10):1126-33.

10. 10.Escaned J, Echavarría-Pinto M, Gorgadze T, Gonzalo N, Armengol F, Hernández R, et al. Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction. EuroIntervention. 2013;8(10):1149-56.

11. 11.Costa JR, Abizaid A, Dudek D, Silber S, Leon MB, Stone GW. Rationale and design of the MGuard for acute ST elevation reperfusion (MASTER) Trial. 2013;82(2):184-90.

12. 12.Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olive-crona G, Omerovic E, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012; 33(5):606-13.

13. 13.Fröbert O, Sarno G, James SK, Saleh N, Lagerqvist B. Effect of stent inflation pressure and post-dilatation on the outcome of coronary artery intervention. A Report of more than 90.000 stent implantations. PLoS ONE [Internet]. 2013 [citado 2013 Jul 18]; 8(2):e56348. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571959/